DF
XLO icon

Dunhill Financial’s Xilio Therapeutics XLO Stock Holding History

Dunhill Financial’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-734
Closed -$6.58K – 2101
2025
Q4 		$6.58K Hold
734
– – ﹤0.01% 557
2025
Q3 		$8.66K Hold
734
– – ﹤0.01% 494
2025
Q2 		$6.99K Hold
734
– – ﹤0.01% 503
2025
Q1 		$7.44K Buy
+734
New +$9.22K ﹤0.01% 477
2024
Q4 		– Sell
-734
Closed -$8.09K – 974
2024
Q3 		$8.09K Hold
734
– – ﹤0.01% 441
2024
Q2 		$9.73K Hold
734
– – 0.01% 296
2024
Q1 		$15.7K Hold
734
– – 0.01% 188
2023
Q4 		$5.65K Buy
+734
New +$14.5K 0.01% 278

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dunhill Financial's XLO Position: Q1 2026 in Review

Dunhill Financial sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 734 shares — an estimated $6.58K sold.

Dunhill Financial first reported a position in XLO in Q4 2023 and held it in 8 quarters. The position peaked at $15.7K in Q1 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Dunhill Financial reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Dunhill Financial sold 734 Xilio Therapeutics shares in Q1 2026, an estimated $6.58K.
  • Dunhill Financial first reported a position in Xilio Therapeutics in Q4 2023 and held it in 8 quarters.
  • Dunhill Financial's Xilio Therapeutics position peaked at $15.7K in Q1 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.